Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
41 hedge funds and large institutions have $33.3M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 10 closing their positions.
0.7% more ownership
Funds ownership: 30% → 30.7% (+0.7%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
2% less funds holding
Funds holding: 42 → 41 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
30% less capital invested
Capital invested by funds: $47.6M → $33.3M (-$14.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Ovata Capital Management
Hong Kong
|
+$3.12M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.18M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.06M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$477K |
| 5 |
D.E. Shaw & Co
New York
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.51M |
| 2 |
Two Sigma Investments
New York
|
-$668K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$505K |
| 4 |
DAM
DLD Asset Management
New York
|
-$265K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$265K |
OPNT Hedge Fund Activity: Q1 2022 in Review
41 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2022, worth a combined $33.3M — down 30% from $47.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of OPNT and 9 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.
The largest buyer was Ovata Capital Management, opening a new position worth an estimated $3.12M. The largest seller was EAM Investors, exiting entirely with an estimated $1.51M sold.
- 41 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2022, down from 42 in Q4 2021.
- Funds reported $33.3M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 30% quarter-over-quarter.
- 9 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of -1 holder.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Ovata Capital Management, an estimated $3.12M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was EAM Investors, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2022.